GlassScriptPhysician profile
Amanda G Mcmasters
NPI 1467970657
$2,983.38
in general payments reported to CMS, 2019-2025
26 companies · $547 in 2025
The $547 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $421 · 2023: $474 · 2024: $1,097 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.60 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $634.72 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $495.00 | 2024-2025 | |
| Amgen INC. | $254.27 | 2021-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $226.66 | 2021-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $213.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $160.71 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.94 | 2023-2025 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $109.59 | 2024-2025 | Glassia |
| Janssen Pharmaceuticals, INC | $91.94 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $84.37 | 2021-2024 | Dupixent |
| Inogen, INC. | $79.40 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.36 | 2023-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $65.66 | 2021-2023 | Verquvo |
| Verona Pharma, INC. | $63.42 | 2025 | Ohtuvayre |
| Kestra Medical Technology Services, INC. | $61.66 | 2024-2025 | Assure Wcd |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.21 | 2022-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $31.53 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $27.17 | 2024 | Uptravi, Opsumit |
| United Therapeutics Corporation | $25.46 | 2023 | Tyvaso |
| Baxter Healthcare | $23.81 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $22.42 | 2021 | |
| Viatris Specialty LLC | $17.94 | 2025 | Yupelri |
| Scpharmaceuticals INC. | $16.61 | 2024 | |
| Amarin Pharma, INC. | $14.61 | 2022 | |
| Mylan Specialty L.P. | $14.42 | 2024 | Yupelri |
| Irhythm Technologies, INC. | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mcmasters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.